OTCMKTS:MAQAF Atlas Arteria (MAQAF) Stock Price, News & Analysis $3.57 0.00 (0.00%) As of 05/2/2025 Add Compare Share Share Stock Analysis Stock AnalysisChartHeadlinesShort InterestBuy This Stock About Atlas Arteria Stock (OTCMKTS:MAQAF) 30 days 90 days 365 days Advanced Chart View Price History Chart DataSkip Price History Chart Get Atlas Arteria alerts:Sign Up Key Stats Today's Range$3.57▼$3.5750-Day Range$3.00▼$3.5752-Week Range$2.73▼$3.82Volume1 shsAverage Volume739 shsMarket CapitalizationN/AP/E RatioN/ADividend Yield2.32%Price TargetN/AConsensus RatingN/A Company OverviewAtlas Arteria Limited owns, develops, and operates toll roads. It holds a 31.14% of interest in the APRR and A79 and 31.17% interest in the ADELAC located in France; 100% interest in the Warnow Tunnel located in Rostock, Germany; 66.67% interest in the Chicago Skyway situated in Chicago and 100% interest in the Dulles Greenway located in Virginia, United States. The company was formerly known as Macquarie Atlas Roads Limited and changed its name to Atlas Arteria Limited in May 2018. Atlas Arteria Limited was incorporated in 2009 and is based in Melbourne, Australia.Read More… Atlas Arteria Stock Analysis - MarketRank™See Top-Rated MarketRank™ Stocks11th Percentile Overall ScoreMAQAF MarketRank™: Atlas Arteria scored higher than 11% of companies evaluated by MarketBeat. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's OpinionN/AAnalyst RatingN/A Consensus RatingThere is not enough analysis data for Atlas Arteria. Earnings and Valuation0.0 / 5Proj. Earnings GrowthN/A Price to Earnings Ratio vs. the MarketThe P/E ratio of Atlas Arteria is -34.69, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Atlas Arteria is -34.69, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings. Short Interest4.0 / 5Short Interest LevelHealthy Percentage of Shares ShortedShort Interest Ratio / Days to CoverAtlas Arteria has a short interest ratio ("days to cover") of 0, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in Atlas Arteria has recently decreased by 13.10%, indicating that investor sentiment is improving significantly. Dividend1.7 / 5Dividend StrengthWeak Dividend LeadershipAtlas Arteria is a leading dividend payer. It pays a dividend yield of 5.02%, putting its dividend yield in the top 25% of dividend-paying stocks.Dividend GrowthAtlas Arteria does not have a long track record of dividend growth.Read more about Atlas Arteria's dividend. Sustainability and ESGN/AEnvironmental ScoreN/A Percentage of Shares ShortedShort Interest Ratio / Days to CoverAtlas Arteria has a short interest ratio ("days to cover") of 0, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in Atlas Arteria has recently decreased by 13.10%, indicating that investor sentiment is improving significantly. News and Social Media0.9 / 5News SentimentN/A News SentimentAtlas Arteria has a news sentiment score of -0.45. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.40 average news sentiment score of Industrials companies.News Coverage This WeekMarketBeat has tracked 1 news article for Atlas Arteria this week, compared to 0 articles on an average week. Company Ownership0.0 / 5Insider TradingN/A Insider Buying vs. Insider SellingIn the past three months, Atlas Arteria insiders have not sold or bought any company stock.Percentage Held by InstitutionsOnly 24.06% of the stock of Atlas Arteria is held by institutions.Read more about Atlas Arteria's insider trading history. Receive MAQAF Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Atlas Arteria and its competitors with MarketBeat's FREE daily newsletter. Email Address MAQAF Stock News HeadlinesMAQAF Atlas Arteria Limited Stapled SecuritiesApril 29, 2025 | seekingalpha.comMorgans Sticks to Its Hold Rating for Atlas Arteria (MAQAF)April 25, 2025 | markets.businessinsider.comWarning: “DOGE Collapse” imminentElon Strikes Back You may already sense that the tide is turning against Elon Musk and DOGE. Just this week, President Trump promised to buy a Tesla to help support Musk in the face of a boycott against his company. But according to one research group, with connections to the Pentagon and the U.S. government, Elon's preparing to strike back in a much bigger way in the days ahead.May 4, 2025 | Altimetry (Ad)Atlas Arteria toll road revenue up 6% as French farmer protests wind downApril 23, 2025 | msn.comWith 73% institutional ownership, Atlas Arteria Limited (ASX:ALX) is a favorite amongst the big gunsMarch 11, 2025 | finance.yahoo.comAtlas Arteria's (ASX:ALX) Solid Earnings May Rest On Weak FoundationsMarch 11, 2025 | finance.yahoo.comVanguard Group Acquires Substantial Stake in Atlas ArteriaMarch 10, 2025 | tipranks.comVanguard Group Reduces Stake in Atlas ArteriaMarch 5, 2025 | tipranks.comSee More Headlines MAQAF Stock Analysis - Frequently Asked Questions How have MAQAF shares performed this year? Atlas Arteria's stock was trading at $2.7260 at the beginning of the year. Since then, MAQAF stock has increased by 31.0% and is now trading at $3.57. View the best growth stocks for 2025 here. How do I buy shares of Atlas Arteria? Shares of MAQAF stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Industry, Sector and Symbol Stock ExchangeOTCMKTS SectorIndustrials Industry Infrastructure Operations Sub-IndustryN/A Current SymbolOTCMKTS:MAQAF CIKN/A Webwww.atlasarteria.com Phone611800621694FaxN/AEmployeesN/AYear FoundedN/AProfitability EPS (Most Recent Fiscal Year)N/A Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet IncomeN/A Net MarginsN/A Pretax MarginN/A Return on EquityN/A Return on AssetsN/A Debt Debt-to-Equity RatioN/A Current RatioN/A Quick RatioN/A Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book ValueN/A Price / BookN/AMiscellaneous Outstanding SharesN/AFree FloatN/AMarket CapN/A OptionableNot Optionable BetaN/A The Best High-Yield Dividend Stocks for 2025Discover the 10 Best High-Yield Dividend Stocks for 2025 and secure reliable income in uncertain markets. Download the report now to identify top dividend payers and avoid common yield traps.Get This Free Report This page (OTCMKTS:MAQAF) was last updated on 5/4/2025 by MarketBeat.com Staff From Our PartnersWarning: “DOGE Collapse” imminentElon Strikes Back You may already sense that the tide is turning against Elon Musk and DOGE. Just this week...Altimetry | SponsoredAltucher: Turn $900 into $108,000 in just 12 months?We are entering the final Trump Bump of our lives. But the biggest returns will not be in the stock market.Paradigm Press | SponsoredThink NVDA’s run was epic? You ain’t seen nothin’ yetAsk most investors and they’ll probably tell you Nvidia is the undisputed AI stock of the decade. In 2023, ...Timothy Sykes | SponsoredThe Robotics Revolution has arrived … and one $7 stock could take off as a result.Robots aren't coming to America in 2025. They are already here. Oxford Economics says, "The Robotics Rev...Weiss Ratings | SponsoredWill May start the next "Great Depression?"You probably haven't heard about this yet... But this could be the biggest wealth building opportunity of t...Behind the Markets | Sponsored🥾⛏️👷♂️ What I Learned From Numerous Mine Visits...Twenty years ago, I made a decision that changed my life. Instead of sitting behind a desk analyzing mining...Golden Portfolio | SponsoredThe Last Time This Happened, Americans Lost BillionsWall Street leaders just held a secret meeting in Las Vegas. What they discussed mirrors 2006 — and the warnin...Banyan Hill Publishing | SponsoredURGENT: This Altcoin Opportunity Won’t Wait – Act NowThe July 23rd Crypto Trigger Could Mark the Beginning of Bitcoin’s Next Big Move Bitcoin’s early 2024 ETF r...Crypto Swap Profits | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Atlas Arteria Limited Please log in to your account or sign up in order to add this asset to your watchlist. Share Atlas Arteria With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.